Plus Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Plus Therapeutics, Inc.
Experts share what they believe are the solutions to key manufacturing challenges, such as lowering cost of goods and centralized manufacturing, in the cell and gene therapy sector.
Deal Snapshot: Building portfolio and commercial infrastructure in Europe, Advanz gets both at a modest price in acquiring Correvio.
Consolidation and acquisitions among contract manufacturers of cell and gene therapies is a growing trend, as Catalent acquires Belgium- and US-based MaSTherCell Global for $315m, and other cell and gene therapy manufacturers address capacity shortages.
Although there was no major acquisition starting out the J.P. Morgan Healthcare Conference, the deal-making flow has been steady. Pfizer licensed a neurodegenerative disease candidate to Biogen, while also selling Axsome rights to reboxetine in narcolepsy and fibromyalgia. Biogen signed a neurology R&D collaboration with CAMP4 as well.
- Generic Drugs
- Other Names / Subsidiaries
- Azaya Therapeutics, Inc.
- Cytori Therapeutics, Inc.